<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005822</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU5199</org_study_id>
    <secondary_id>U01CA062502</secondary_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CWRU-5199</secondary_id>
    <secondary_id>NCI-T99-0099</secondary_id>
    <nct_id>NCT00005822</nct_id>
  </id_info>
  <brief_title>SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer</brief_title>
  <official_title>A Phase I Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 and Doxorubicin in Inflammatory Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: SU5416 may stop the growth of breast cancer by stopping blood flow to the tumor.&#xD;
      Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop&#xD;
      growing or die. Combining SU5416 with chemotherapy may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining SU5416 and doxorubicin in&#xD;
      treating patients who have stage IIIB or stage IV inflammatory breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of SU5416 and doxorubicin in patients with stage&#xD;
           IIIB or IV inflammatory breast cancer.&#xD;
&#xD;
        -  Determine the overall response, response rate, and progression-free survival rate of&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the antiangiogenic effects of this regimen in these patients.&#xD;
&#xD;
        -  Assess the relationship of plasma levels of these drugs with safety and efficacy in&#xD;
           these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive doxorubicin IV continuously over 72 hours on days 1-3 of course 1. For all&#xD;
      subsequent courses, patients receive doxorubicin as in course 1 and SU5416 IV over 1 hour&#xD;
      twice weekly (on days 1 and 4) beginning on week 2 of course 2. Treatment repeats every 21&#xD;
      days for 5 courses in the absence of disease progression or unacceptable toxicity. After&#xD;
      chemotherapy, all patients undergo a modified radical mastectomy and radiotherapy to the&#xD;
      chest wall and regional lymph nodes. Patients with estrogen or progesterone receptor positive&#xD;
      disease receive oral tamoxifen for 5 years after radiotherapy.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of SU5416 and doxorubicin until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an&#xD;
      additional 3 patients may be treated at that dose level.&#xD;
&#xD;
      Patients are followed every 3 months until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 6-9&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <completion_date type="Actual">October 2003</completion_date>
  <primary_completion_date type="Actual">December 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose of SU5416 and doxorubicin in patients with stage IIIB or IV inflammatory breast cancer.</measure>
    <time_frame>Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.</time_frame>
  </primary_outcome>
  <enrollment type="Actual">21</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Patients receive doxorubicin IV continuously over 72 hours on days 1-3 of course 1. For all subsequent courses, patients receive doxorubicin as in course 1. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaxanib</intervention_name>
    <description>For all subsequent courses, after course 1 patients SU5416 IV over 1 hour twice weekly (on days 1 and 4) beginning on week 2 of course 2. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.</description>
    <other_name>SU5416</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>Patients undergo a modified radical mastectomy.</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Patients undergo radiotherapy to the chest wall and regional lymph nodes.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen</intervention_name>
    <description>Patients with estrogen or progesterone receptor positive disease receive oral tamoxifen for 5 years after radiotherapy.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed stage IIIB or IV (supraclavicular lymph node&#xD;
             involvement or metastasis) inflammatory breast cancer&#xD;
&#xD;
               -  Primary or secondary&#xD;
&#xD;
          -  No brain metastases or primary brain tumors&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,500/mm^3&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 9.0 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT less than 2 times upper limit of normal&#xD;
&#xD;
          -  PT and PTT normal OR&#xD;
&#xD;
          -  INR less than 1.1&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF at least 50% by MUGA&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No uncompensated coronary artery disease&#xD;
&#xD;
          -  No myocardial infarction or unstable angina within the past 6 months&#xD;
&#xD;
          -  No deep venous or arterial thrombosis within the past 3 months&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No history of pulmonary embolism within the past 3 months&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of diabetes mellitus with severe peripheral vascular disease&#xD;
&#xD;
          -  No other prior or concurrent malignancies within the past 10 years except inactive&#xD;
             nonmelanomatous skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No other uncontrolled illnesses&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent epoetin alfa or filgrastim (G-CSF)&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens allowed&#xD;
&#xD;
          -  No prior doxorubicin or other anthracycline&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Prior radiotherapy allowed&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beth A. Overmoyer, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 10, 2010</last_update_submitted>
  <last_update_submitted_qc>June 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Beth A. Overmoyer, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>inflammatory breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Inflammatory Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

